CN
CN
Our latest
Creative Biosciences
Good News | Lunsafe® Receives ANVISA Registration Approval in Brazil, Setting Sail for the Latin American Market!

On August 17, 2026, Lunsafe® — the Methylation Detection Kit for Human HOXB4 and SRCIN1 Genes (Real-Time PCR), independently developed by Creative Biosciences (Guangzhou) Co., Ltd. — was officially granted registration approval by Brazil’s National Heal

Aug 26 , 2026
Media Coverage
Authoritative media releases


Read more
Press releases
Good News | Lunsafe® Receives ANVISA Registration Approval in Brazil, Setting Sail for the Latin American Market!
Aug 26 , 2026
Creative Biosciences Releases Annual Real-World Application Data from Over 1.29 Million Colosafe® Tests
Jan 12 , 2026
Creative Biosciences Showcases at the 2026 Guangzhou Medical Expo, Driving Tumor Early-Screening Development in the Greater Bay Area
Aug 26 , 2026
Creative Biosciences Recognized on the Hurun Future Unicorns: Global Gazelles Index 2025
Jan 27 , 2026
Creative Biosciences Expands in Latin America, Bringing Colosafe® Closer to Local Communities for Early Cancer Detection
Nov 02 , 2025
Lunsafe® Wins NMPA Approval, Pioneering Noninvasive Early Detection of Lung Cancer in China
Jun 01 , 2025
Creativebio Made Debut Presence at Life Science Innovation Northwest 2025
May 06 , 2025
Creative Biosciences Expands Global Footprint with New Seattle Branch
Mar 21 , 2025
One Million Tests of Colosafe Realized in Real World Practice
Feb 20 , 2025
CreativeBio Is Exhibiting at MEDICA 2022
Nov 15 , 2022
Colosafe® Gained Market Entry in Mexico
Jan 23 , 2025
CreativeBio,the Leading Enterprise in Cancer Screening,Completed Rd D Venture Capital Financing of RMB 560 Million Led by Alibaba
Oct 20 , 2021

No. 10 Fenghuang Wu Road
Huangpu District
Guangzhou, Guangdong, 510555
P.R. China


Contact us at

T: +001-206-717-2769
Email: info@creativebio.cn


copyright ©2025 Creative Biosciences (Guangzhou) CO., Ltd
Legal mention